# COVID-19 vaccination in Thailand

Total number of people who have received vaccinations in Thailand as of 8 Nov 2021 * Percentage of population with right to medical treatment
Vaccines delivered per pharmaceutical company as of 8 Nov
COVID-19 vaccination in Thailand is an ongoing mass immunization in response to the ongoing pandemic in the country.

## Background

In November 2020, the authorities ordered 26 million doses of vaccine from AstraZeneca, which reported 70% overall efficacy. It requires 2 doses of vaccine per person, so the quantity ordered would only cover 13 million people. Prayut cabinet later approved budget for ordering 35 million additional doses in January 2021. Siam Bioscience, a company owned by King Vajiralongkorn, will received technological transfer for co-investment. The authorities also imported 2 million doses of vaccine from Sinovac, a Chinese company which Thai conglomerate Charoen Pokphand invested in, during February to April 2021.
Likewise, the Thai government also stepped up its attempt to produce its homegrown vaccines amidst criticism, with "ChulaCov19" and set to begin trials in May 2021. Phase I testing of the NDV-HXP-S vaccine began at Mahidol University in March 2021.
In July 2021, the National Vaccine Institute apologized for slow vaccine deployment. Meanwhile, the government's prior commitment to secure 61 million doses of AstraZeneca vaccine became doubted after a leaked document showed that the company would deliver no more than 60 percent of the number planned per month. A virology advisor also endorsed an untested plan to mix AstraZeneca and Sinovac vaccines. There was already a report of death from the practice, but health professionals said they have to rule out other causes first.

## Vaccines used
### National Vaccines

Free Vaccines which are provided under the policies of the Ministry of Public Health.
| Vaccine name | Doses ordered (excluding donation) | Doses arrived (including donation) | Approval (EUA) | First Arrival | Deployment |
| Oxford–AstraZeneca | 61 million | 25.5 million | 20 January 2021 | 24 February 2021 | 28 February 2021 |
| CoronaVac | 31.1 million | 26.52 million | 22 January 2021 | 24 February 2021 | 28 February 2021 |
| Janssen | 5 million | unknown | 25 March 2021 | Late June | 26 July 2021 |
| Pfizer–BioNTech | 30 million | 3.5 million | 24 June 2021 | 30 July 2021 | 5 Aug 2021 |

### Optional Vaccines

Vaccines that are not in the policies of the Ministry of Public Health. Orders are made through government organizations but the cost of vaccination will not be supported by the government. However, people who get vaccinated by these vaccines are still counted in the national vaccination programme.
| Vaccine name | Distributor | Doses planned or ordered | Doses arrived | Approval (EUA) | First Arrival | Deployment |
| Moderna | Government Pharmaceutical Organization | 5 million | 0.5602 million | 13 May 2021 | 1 Nov 2021 | 5 Nov 2021 |
| Moderna | Chulabhorn Royal Academy | 8 million | Not yet | 13 May 2021 | Not yet | Not yet |
| Sinopharm BIBP (BBIBP-CorV) | Chulabhorn Royal Academy | 15 million | 15 million | 28 May 2021 | 20 June 2021 | 25 June 2021 |

### Vaccines pending approval

* Sputnik V
* Covaxin

## Vaccination Procedures

Vaccination procedures used in Thailand.
| First Dose | Second Dose | Third Dose | Fourth Dose | Dose Interval |
| CoronaVac or Sinopharm BIBP | CoronaVac or Sinopharm BIBP | Oxford–AstraZeneca or Pfizer–BioNTech or Moderna | Oxford–AstraZeneca or Pfizer–BioNTech or Moderna | 2–4 weeks (2nd) 4 weeks (3rd) 3 month (4th) |
| CoronaVac or Sinopharm BIBP | Oxford–AstraZeneca | Oxford–AstraZeneca or Pfizer–BioNTech or Moderna | Oxford–AstraZeneca or Pfizer–BioNTech or Moderna | 3–4 weeks (2nd) 3 month (3rd and 4th) |
| CoronaVac or Sinopharm BIBP | Pfizer–BioNTech or Moderna | Pfizer–BioNTech or Moderna | Pfizer–BioNTech or Moderna | 3–4 weeks (2nd) 6 month (3rd) 3 month (4th) |
| Oxford–AstraZeneca | Oxford–AstraZeneca | Pfizer–BioNTech or Moderna | Pfizer–BioNTech or Moderna | 10–16 weeks (2nd) 3 month (3rd and 4th) |
| Oxford–AstraZeneca | Pfizer–BioNTech or Moderna | Pfizer–BioNTech or Moderna | Pfizer–BioNTech or Moderna | 4–12 weeks (2nd) 6 month (3rd) 3 month (4th) |
| Pfizer–BioNTech or Moderna | Pfizer–BioNTech or Moderna | Pfizer–BioNTech or Moderna | Pfizer–BioNTech or Moderna | 4–12 weeks (2nd) 6 month (3rd) 3 month (4th) |